Intec Pharma (NTEC) Announces Quarterly Earnings Results

Intec Pharma (NASDAQ:NTEC) released its earnings results on Friday. The biotechnology company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.03, MarketWatch Earnings reports.

Shares of Intec Pharma stock traded up $0.01 during midday trading on Friday, hitting $5.89. 126,488 shares of the company traded hands, compared to its average volume of 130,876. The firm has a market capitalization of $193.02 million, a PE ratio of -3.57 and a beta of 0.71. Intec Pharma has a 12 month low of $3.55 and a 12 month high of $7.50.

Several equities analysts have commented on the stock. Roth Capital assumed coverage on shares of Intec Pharma in a report on Friday, October 5th. They issued a “buy” rating and a $8.50 target price on the stock. Oppenheimer set a $15.00 target price on shares of Intec Pharma and gave the company a “buy” rating in a report on Sunday, September 30th. HC Wainwright set a $16.00 target price on shares of Intec Pharma and gave the company a “buy” rating in a report on Thursday, August 16th. Finally, Zacks Investment Research raised shares of Intec Pharma from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a report on Wednesday, October 17th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $11.40.

COPYRIGHT VIOLATION WARNING: This article was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2018/11/10/intec-pharma-ntec-announces-quarterly-earnings-results.html.

About Intec Pharma

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers

Earnings History for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply